Latest Content

Facing Mortality After Cancer, and Choosing to Live Fully

October 20th 2025, 1:00pm

By Karen Cohn

Article

After her follicular lymphoma diagnosis, Karen Cohn reflects on how cancer reshaped her view of mortality and her choice to keep living fully.

Ivonescimab Combo Improves Progression-Free Survival in Advanced NSCLC

October 19th 2025, 9:15pm

By Kristi Rosa

Article

Ivonescimab plus chemotherapy significantly improved progression-free survival versus Tevimbra advanced squamous non–small cell lung cancer.

Sacituzumab Tirumotecan Improves Survival in EGFR-Mutated Non-Small Cell Lung Cancer

October 19th 2025, 8:44pm

By Gina Mauro

Article

Sacituzumab tirumotecan cut risk of progression or death by 51% versus chemotherapy in EGFR-mutated NSCLC after tyrosine kinase inhibitor resistance.

Tiragolumab Treatment Combo Misses Mark in Advanced Liver Cancer

October 19th 2025, 8:13pm

By Spencer Feldman

Article

Tiragolumab added to Tecentriq plus Avastin did not improve progression-free survival in untreated advanced hepatocellular carcinoma, phase 3 data show.

Imfinzi Combo Improves Progression Free Survival in Ovarian Cancer

October 19th 2025, 7:50pm

By Kyle Doherty

Article

Platinum chemo with Imfinzi, Avastin, and Lynparza improved progression-free survival versus chemo and Avastin but did not extend overall survival.

Loqtorzi Extends Survival in HER2-Positive Advanced Urothelial Cancer

October 19th 2025, 7:26pm

By Tim Cortese

Article

Loqtorzi improved progression-free and overall survival versus chemotherapy in HER2-expressing advanced urothelial cancer.

Supplemental Xtandi Does Not Improve Metastasis-Free Survival in High-Risk Prostate Cancer

October 19th 2025, 6:57pm

By Ryan Scott

Article

Adding Xtandi to androgen deprivation therapy and radiation did not significantly improve metastasis-free survival in high-risk localized prostate cancer.

Imfinzi With Chemo Produces Inconclusive Outcomes in Phase 3 Mesothelioma Study

October 19th 2025, 6:37pm

By Sabrina Serani

Article

In phase 3 DREAM3R, first-line Imfinzi plus chemotherapy showed survival and response benefits in advanced mesothelioma, but results were inconclusive.

Tecentriq Plus Chemo Shows Comparable Survival in Endometrial Cancer

October 19th 2025, 6:18pm

By Roman Fabbricatore

Article

Adding Tecentriq to chemo resulted in survival outcomes comparable to placebo plus chemo in patients with advanced or recurrent endometrial cancer.

Trodelvy in Metastatic Triple-Negative Breast Cancer Supported by Phase 3 Trial

October 19th 2025, 5:49pm

By Kristie L. Kahl

Article

Trodelvy reduced risk of disease progression or death versus chemotherapy in patients with previously untreated metastatic triple-negative breast cancer.

Truqap Extends Radiographic Progression-Free Survival in Some With Prostate Cancer

October 19th 2025, 5:09pm

By Silas Inman

Article

Adding Truqap to Zytiga, prednisone, and ADT extended radiographic progression-free survival by 7.5 months in PTEN-deficient prostate cancer.

Tiragolumab Plus Tecentriq Doesn’t Improve NSCLC Outcomes

October 19th 2025, 1:55am

By Jason M Broderick

Article

Consolidation tiragolumab plus Tecentriq does not improve progression-free survival in advanced lung cancer compared to Imfinzi.

HR+/HER2- Metastatic Breast Cancer Progression Improved With Sac-TMT

October 19th 2025, 1:25am

By Andrea Eleazar, MHS

Article

Sac-TMT improved progression-free survival in patients with HR+/HER2– breast cancer.

Presurgical Enhertu Combo Elicits Response Benefit in HER2+ Early Breast Cancer

October 19th 2025, 12:28am

By Chris Ryan

Article

Neoadjuvant Enhertu then THP improved pathological complete response rate in patients with high-risk, HER2-positive early breast cancer.

Similar Incidence of Second Primary Tumors After Libtayo or Placebo for CSCC

October 18th 2025, 11:32pm

By Jax DiEugenio

Article

Postsurgical Libtayo and placebo showed similar rates of second primary tumors in high-risk CSCC